EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Baseline characteristics of Ghanaian children and adults enrolled in PIVOT , a randomised clinical trial of hydroxyurea in HbSC disease in sub‐Saharan Africa

Catherine I Segbefia iD, Luke R Smart iD, Susan E Stuber, Kwesi N Amissah-Arthur iD, Klenam Dzefi-Tettey iD, Priscilla Ekpale, Enoch Mensah, Adam C Lane, William Ghunney iD, Lily Gloria Tagoe, Alpha Oteng, Emmanuella Amoako und 3 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19832 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Catherine I Segbefia und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child Health, University of Ghana Medical School, Accra, Ghana. Hauptthemen laut MEDLINE: Hydroxyurea. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Theravia, NHGRI NIH HHS, Optos Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HbSC disease is a common form of sickle cell disease with significant morbidity and early mortality. Whether hydroxyurea is beneficial for HbSC disease is unknown. Prospective Identification of Variables as Outcomes for Treatment (PIVOT, Trial ID PACTR202108893981080) is a double‐blind, randomised, placebo‐controlled phase II trial of hydroxyurea for people with HbSC, age 5–50 years, in Ghana. After screening, participants were randomised to placebo (standard of care) or hydroxyurea. The primary outcome is the cumulative incidence of haematological toxicities during 12 months of blinded treatment; secondary outcomes include multiple laboratory and clinical assessments. Between April 2022 and June 2023, 112 children and 102 adults were randomised, including 44% females and average age 21.6 ± 14.5 years. Participants had substantial morbidity including previous hospitalisations (93%), vaso‐occlusive events (86%), malaria (79%), often received transfusions (20%), with baseline haemoglobin 11.0 ± 1.2 g/dL and foetal haemoglobin 1.8% ± 1.5%. The spleen was palpable in six children and one adult, and ultrasonographic volumes were collected. Proliferative sickle retinopathy was common (30% children, 75% adults), but proteinuria was less common (3% children, 8% adults). Whole blood viscosity, ektacytometry, point‐of‐sickling, transcranial Doppler, near‐infrared spectrometry (NIRS), 6‐minute walk, and quality of life were also measured. Now fully enrolled, PIVOT will document the safety and potential benefits of hydroxyurea on clinical and laboratory outcomes in HbSC disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydroxyureaHumansFemaleMaleChildAdultGhanaAdolescentChild, PreschoolMiddle AgedYoung AdultAntisickling AgentsAnemia, Sickle CellDouble-Blind MethodHemoglobin SC Disease

Stichwörter der Autor:innen

HbSC diseaseadultschildrenhydroxyureastudy endpointssub‐Saharan Africa

Substanzen

HydroxyureaAntisickling Agents

Autor:innen und Institutionen

  • Department of Child Health, University of Ghana Medical School, Accra, Ghana.
  • Department of Child Health, Korle Bu Teaching Hospital, Accra, Ghana.
  • Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Global Health Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Ophthalmology Unit, Department of Surgery, University of Ghana Medical School, Accra, Ghana.

ORCID-Profile: Catherine I Segbefia, Luke R Smart, Kwesi N Amissah-Arthur, Klenam Dzefi-Tettey, William Ghunney, Teresa S Latham, Yvonne A Dei-Adomakoh, Russell E Ware

Förderung

  • Theravia
  • NHGRI NIH HHS
  • Optos Inc.
  • NHLBI NIH HHS
  • NIH-H3 Eyes of Africa
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Segbefia, C. I., Smart, L. R., Stuber, S. E., Amissah-Arthur, K. N., Dzefi-Tettey, K., Ekpale, P., Mensah, E., Lane, A. C., Ghunney, W., Tagoe, L. G., Oteng, A., Amoako, E., Latham, T. S., Dei-Adomakoh, Y. A., & Ware, R. E. (2024). Baseline characteristics of Ghanaian children and adults enrolled in PIVOT , a randomised clinical trial of hydroxyurea in HbSC disease in sub‐Saharan Africa. British Journal of Haematology. https://doi.org/10.1111/bjh.19832

Vancouver

Segbefia CI, Smart LR, Stuber SE, Amissah-Arthur KN, Dzefi-Tettey K, Ekpale P, et al. Baseline characteristics of Ghanaian children and adults enrolled in PIVOT , a randomised clinical trial of hydroxyurea in HbSC disease in sub‐Saharan Africa. British Journal of Haematology. 2024. doi:10.1111/bjh.19832

BibTeX
@article{Segbefia2024,
  author = {Segbefia, Catherine I and Smart, Luke R and Stuber, Susan E and Amissah-Arthur, Kwesi N and Dzefi-Tettey, Klenam and Ekpale, Priscilla and Mensah, Enoch and Lane, Adam C and Ghunney, William and Tagoe, Lily Gloria and Oteng, Alpha and Amoako, Emmanuella and Latham, Teresa S and Dei-Adomakoh, Yvonne A and Ware, Russell E},
  title = {Baseline characteristics of Ghanaian children and adults enrolled in PIVOT , a randomised clinical trial of hydroxyurea in HbSC disease in sub‐Saharan Africa},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19832}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche